Vitiligo Management: Current Landscape and Future Directions – A Comprehensive Review

Vitiligo is an acquired pigmentary disorder marked by the progressive loss of melanocytes, resulting in well-defined depigmented macules and patches on the skin and mucous membranes. The condition affects about 0.5–2% of the world’s population and can occur at any age or in either sex. Although the exact cause remains uncertain, current evidence supports a multifactorial origin involving genetic predisposition, autoimmune responses, oxidative stress, and environmental triggers. The disease is broadly categorized into segmental and non-segmental types, each exhibiting distinct patterns of distribution and progression. Diagnosis is mainly clinical, aided by tools such as Wood’s lamp examination and dermoscopy to assess disease activity and stability. Management of vitiligo requires an individualized, multimodal approach. Topical corticosteroids, calcineurin inhibitors, and phototherapy remain standard first-line therapies, while surgical procedures are reserved for stable and localized lesions. In recent years, targeted therapies such as Janus kinase (JAK) inhibitors and antioxidant-based regimens have demonstrated promising efficacy, expanding the therapeutic landscape. Despite these advances, complete and sustained repigmentation remains a major challenge, and relapse is common. The psychosocial impact of vitiligo is considerable, underscoring the need for holistic management strategies that address both physical and emotional well-being. This review provides a comprehensive overview of the epidemiology, pathogenesis, clinical features, diagnostic techniques, and current as well as emerging treatments for vitiligo, highlighting recent scientific progress and future research directions.